Dr. Preston Noon, PharmD, MBA is Co-Founder and Partner at Agent Capital since 2017. Agent Capital is a healthcare venture capital firm that has invested in more than 20 companies that address unmet patient needs. Preston supports all Agent Capital fund activities, including leading new investments, portfolio management, and maintaining back-office functions. Prior to Agent Capital, Preston worked in the pharmaceutical industry for Bristol-Myers Squib, Bayer, and Baxalta (a NYSE-listed spinout from Baxter Healthcare acquired by Shire PLC in 2017). At Bayer, Preston was a post-doctoral Associate for the U.S. Business Development and Licensing group, where he worked on in-licensing pharmaceutical assets and asset divestitures. Prior to Bayer, Preston was a global medical affairs analyst at Bristol-Myers Squibb. He began his career in the pharmaceutical industry working at Bristol-Myers Squibb to support clinical trial operations, specifically to monitor and improve enrollment timelines for next generation immuno-oncology assets including ipilimumab and nivolumab, which are now approved. Preston is a Kauffman Fellow, member of Class 23. He received a PharmD and MBA each from the University of Connecticut.